Anxiolytic and antidepressant properties of methylene blue in animal models

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
L Eroğlu, B Cağlayan

Abstract

Methylene blue (MB) has been intermittently used in manic depressive illness over the past century. However, to our knowledge, it has not been studied in the behavioural animal models. The present study was designed to evaluate whether the intravenous (i.v.) administration of MB in a dose range of 1.87-60 mg kg-1 would affect the performance of rats in the elevated plus-maze and the forced swimming (FST) tests. In the plus-maze, MB in doses ranging from 3.25 to 30 mg kg-1 significantly increased the percentage of open arm entries and exhibited an inverted U-shaped dose-response curve. Over a dose range, 7.5-30 mg kg-1, MB also increased time spent in open arms. These data suggest that MB has anxiolytic properties. On the other hand, MB, at doses of 15 and 30 mg kg-1 significantly decreased the immobility time in the FST and behaved as an antidepressant compound in these doses. As known, MB has prominent effects on the nitrergic system; Nitric oxide (NO) produced from L-arginine by the enzyme NO-synthase (NOS) activates soluble guanylyl cyclase (sGC) and exerts its effects on tissues through cGMP. MB acts as a direct inhibitor of NOS as well as of sGC. It also inactivates NO extracellularly through generation of superoxide anion...Continue Reading

Citations

May 24, 2000·British Journal of Pharmacology·G WegenerR Rosenberg
Jun 24, 2008·Neuropsychiatric Disease and Treatment·Frasia OosthuizenBrian H Harvey
Aug 23, 2002·Behavioural Brain Research·Ida Louise HeibergRaben Rosenberg
Jul 11, 2008·Critical Reviews in Toxicology·Edward J Calabrese
Apr 25, 2008·Critical Reviews in Toxicology·Edward J Calabrese
Jun 13, 2012·Pharmacology, Biochemistry, and Behavior·Morteza PiriMohammad Reza Zarrindast
Dec 27, 2011·Toxicology and Applied Pharmacology·Anél PetzerJacobus P Petzer
Jun 15, 2011·Journal of Clinical Anesthesia·Akgün Ebru SalmanÜlkü Aypar
Sep 8, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Neeraj Gilhotra, Dinesh Dhingra
Sep 16, 2008·European Journal of Pharmacology·Patrícia de Souza BrocardoAna Lúcia S Rodrigues
Sep 9, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Cristiano R JesseCristina W Nogueira
Mar 24, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ashish Dhir, S K Kulkarni
Dec 20, 2003·Annals of the New York Academy of Sciences·Ian A Paul, Phil Skolnick
May 6, 2011·British Journal of Pharmacology·Murat OzToni S Shippenberg
Dec 24, 2010·British Journal of Pharmacology·Bronwyn M GrahamRick Richardson
Sep 18, 2009·Medicinal Research Reviews·Murat OzGeorge A Petroianu
Aug 18, 2004·Neurochemistry International·Jos PrickaertsArjan Blokland
Apr 21, 2006·Brain Research Bulletin·Vanessa Beijamini, Francisco Silveira Guimarães
Aug 13, 2005·Neuroscience and Biobehavioral Reviews·F S GuimarãesA C B de Lucca
Jun 26, 2015·Pharmacognosy Magazine·Mohammad Hayatul IslamMohammad Tariq Salman
Jan 11, 2014·Behavioural Brain Research·Vivian Binder NeisAna Lúcia S Rodrigues
Jun 5, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sattar OstadhadiAhmad-Reza Dehpour
Nov 26, 2009·The American Journal of Chinese Medicine·Pei-Ju ChenLee-Yan Sheen
Jun 11, 2016·The British Journal of Psychiatry : the Journal of Mental Science·Martin AldaGlenda MacQueen
Jan 22, 2002·Neuroscience and Biobehavioral Reviews·R M De OliveiraF S Guimarães
Dec 10, 1999·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·R W de-Oliveira, F S Guimarães
Jan 20, 2010·Pharmaceuticals·Gregers Wegener, Vallo Volke
Aug 26, 2017·Molecular Neurobiology·Donovan TuckerQuanguang Zhang
Aug 16, 2001·Critical Reviews in Toxicology·E J Calabrese, L A Baldwin
Aug 16, 2001·Critical Reviews in Toxicology·E J Calabrese
Mar 7, 2006·Psychopharmacology·Sâmia Regiane Lourenço Joca, Francisco Silveira Guimarães
Oct 25, 2013·Food & Function·Luana M ManossoAna Lúcia S Rodrigues
Aug 2, 2017·Metabolic Brain Disease·Anzelle DelportJacobus P Petzer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.